CYP1A2, a member of the cytochrome P450 monooxygenase family, is a membrane-bound protein which oxidatively metabolizes a wide range of drugs, toxins and endogenous compounds. It is expressed predominantly in the liver where it comprises about 15% of the total P450 present.
CYP1A2 is integral in drug metabolism, handling substances such as caffeine, aflatoxin B1, melatonin, bilirubin, estrogens, and a host of clinical medications including clozapine, theophylline, and tizanidine. It also contributes to the activation of certain procarcinogens, such as those found in cooked food and tobacco products, highlighting its importance in both pharmacology and toxicology. It is inhibited by a range of chemicals, including fluoroquinolones, oral contraceptives, and some foods. AkrivisBio’s CYP1A2 Inhibitor Screening Kit is a simple, sensitive way to assess the effect of various compounds on its enzymatic efficiency.
